Related Experiment Videos
Early-stage Hodgkin's disease
1First Department of Internal Medicine, University Hospital Cologne, Joseph-Stelzmann-Str. 9, 50924 Cologne, Germany.
Insights
Treatment for early-stage Hodgkin's disease (HD) is evolving. Current approaches for favorable early-stage HD combine chemotherapy with involved-field irradiation, while unfavorable early-stage HD receives more intensive chemotherapy and irradiation.
Area of Science:
- Oncology
- Radiation Oncology
- Clinical Medicine
Background:
- Hodgkin's disease (HD) staging dictates treatment strategy.
- Historically, early-stage HD (Stages I-IIIA) received different management than advanced stages.
- Early-stage HD with risk factors indicated a worse prognosis, necessitating revised treatment protocols.
Purpose of the Study:
- To outline the evolving treatment paradigms for early-stage Hodgkin's disease.
- To differentiate management strategies based on risk stratification within early-stage HD.
- To highlight the shift away from extended-field irradiation in favor of more targeted therapies.
Main Methods:
- Review of historical and current treatment protocols for early-stage Hodgkin's disease.
- Analysis of treatment outcomes based on disease stage and risk factors.
- Comparison of extended-field irradiation with involved-field irradiation and chemotherapy combinations.
Main Results:
- Extended-field (EF) irradiation, once standard, is being abandoned due to high relapse rates and long-term toxicity.
- Favorable early-stage HD is now treated with mild chemotherapy and involved-field (IF) irradiation.
- Early-stage unfavorable (intermediate) HD is managed with four cycles of chemotherapy plus IF irradiation.
Conclusions:
- Treatment for early-stage Hodgkin's disease has significantly advanced.
- Current strategies prioritize less toxic, more targeted approaches like involved-field irradiation combined with chemotherapy.
- Risk stratification is crucial for tailoring effective Hodgkin's disease treatment.
Abstract:
Treatment of Hodgkin's disease (HD) is strictly dependent on stage. Historically, early-stage HD included the limited stages I, II, and IIIA (according to the Cotswolds modification of the Ann Arbor classsification), whereas advanced HD included stage III with B symptoms and stage IV. It was then observed that early-stage HD with certain clinical risk factors had a significantly worse outcome. As a consequence, several studies defined these patients as suffering from early-stage unfavorable (or intermediate-stage) HD, demanding a more aggressive treatment. The treatment of early-stage HD is changing strikingly. Until recently, extended-field (EF) irradiation has been considered the standard treatment. However, because of the recognition of its high relapse rate and fatal long-term effects, EF radiotherapy is now being abandoned by most study groups. Instead, for favorable early-stage HD, mild chemotherapy for control of occult disease is combined with involved-field (IF) irradiation. In early-stage unfavorable (intermediate) HD, four cycles of chemotherapy plus IF irradiation is accepted as standard treatment.